Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Peptides from Natural or Rationally Designed Sources Can Be Used in Overweight, Obesity, and Type 2 Diabetes Therapies

Full text
Author(s):
Gewehr, Mayara C. F. [1] ; Silverio, Renata [2] ; Rosa-Neto, Jose Cesar [3] ; Lira, Fabio S. [4] ; Reckziegel, Patricia [5] ; Ferro, Emer S. [1]
Total Authors: 6
Affiliation:
[1] Univ Sao Paulo, Biomed Sci Inst, Dept Pharmacol, Sao Paulo 05508000 - Brazil
[2] Fed Univ Santa Catarina UFSC, Ctr Biol Sci, Dept Pharmacol, Florianopolis 88040900, SC - Brazil
[3] Univ Sao Paulo, Biomed Sci Inst, Dept Cell & Dev Biol, Sao Paulo 05508000 - Brazil
[4] Sao Paulo State Univ UNESP, Dept Phys Educ, Presidente Prudente 19060900 - Brazil
[5] Fed Univ Sao Paulo UNIFESP, Natl Inst Pharmacol & Mol Biol INFAR, Dept Pharmacol, Sao Paulo 05508000 - Brazil
Total Affiliations: 5
Document type: Review article
Source: Molecules; v. 25, n. 5 MAR 1 2020.
Web of Science Citations: 0
Abstract

Overweight and obesity are among the most prominent health problems in the modern world, mostly because they are either associated with or increase the risk of other diseases such as type 2 diabetes, hypertension, and/or cancer. Most professional organizations define overweight and obesity according to individual body-mass index (BMI, weight in kilograms divided by height squared in meters). Overweight is defined as individuals with BMI from 25 to 29, and obesity as individuals with BMI >= 30. Obesity is the result of genetic, behavioral, environmental, physiological, social, and cultural factors that result in energy imbalance and promote excessive fat deposition. Despite all the knowledge concerning the pathophysiology of obesity, which is considered a disease, none of the existing treatments alone or in combination can normalize blood glucose concentration and prevent debilitating complications from obesity. This review discusses some new perspectives for overweight and obesity treatments, including the use of the new orally active cannabinoid peptide Pep19, the advantage of which is the absence of undesired central nervous system effects usually experienced with other cannabinoids. (AU)

FAPESP's process: 16/04000-3 - Pharmacology of oligopeptidases and intracellular peptides
Grantee:Emer Suavinho Ferro
Support Opportunities: Research Projects - Thematic Grants
FAPESP's process: 15/20657-0 - Evaluation of hemopressin (HP) pharmacological use on obesity treatment
Grantee:Patrícia Reckziegel
Support Opportunities: Scholarships in Brazil - Post-Doctoral